Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Claudin 6 Protein-VLP (CLDN6) (AA 1-219)

CLDN6 Spezies: Maus Wirt: HEK-293 Cells VLP > 95 % as determined by HPLC ELISA, Imm, Func, SPR Active
Produktnummer ABIN7448164
  • Target Alle Claudin 6 (CLDN6) Proteine anzeigen
    Claudin 6 (CLDN6)
    Protein-Typ
    VLP
    Biologische Aktivität
    Active
    Proteineigenschaft
    AA 1-219
    Spezies
    • 13
    • 1
    • 1
    Maus
    Quelle
    • 9
    • 2
    • 2
    • 1
    • 1
    HEK-293 Cells
    Applikation
    ELISA, Immunogen (Imm), Functional Studies (Func), Surface Plasmon Resonance (SPR)
    Verwendungszweck
    Mouse Claudin 6 Protein-VLP
    Sequenz
    Met1-Val219
    Produktmerkmale
    Recombinant Mouse Claudin 6 Protein-VLP is expressed from HEK293.It contains Met1-Val219.
    Reinheit
    > 95 % as determined by HPLC
    Sterilität
    0.22 μm filtered
    Endotoxin-Niveau
    Less than 1EU per μg by the LAL method.
    Biological Activity Comment
    Immobilized Mouse Claudin 6 VLP at 5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-Claudin6 Antibody, mFc Tag with the EC50 of 6.6ng/ml determined by ELISA.
    Top Product
    Discover our top product CLDN6 Protein
  • Applikationshinweise
    • Antibody Discovery: Immunization, Screening, Functional Characterization
    • Affinity determination: ELISA, SPR
    • In vivo pharmacokinetic analysis
    • CMC method development
    • CAR-T Positive Rate Detection
    • Blood sample determination: ELISA
    Kommentare

    Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

    Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

    Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Supplied as 0.22μm filtered solution in PBS ( pH 7.4). Notice: If you need it for immunization, Do Not use any adjuvant.
    Lagerung
    -80 °C
    Informationen zur Lagerung
    Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    Haltbarkeit
    12 months
  • Target
    Claudin 6 (CLDN6)
    Andere Bezeichnung
    Claudin 6 (CLDN6 Produkte)
    Synonyme
    cldn4l2 Protein, cldn6 Protein, CLDN6 Protein, AL024037 Protein, claudin 6, gene 1 L homeolog Protein, claudin 6 Protein, cldn6.1.L Protein, CLDN6 Protein, Cldn6 Protein
    Hintergrund
    Claudin-6 is a multipass transmembrane protein in the Claudin family. Claudin-6 is expressed by epithelial cells where it participates in tissue development and the maintenance of tight junction integrity. Human Claudin-6 shares 88 % and 86 % amino acid sequence identity with mouse and rat Claudin-6, respectively.
    Molekulargewicht
    24.60 kDa.
    UniProt
    Q9Z262
    Pathways
    Hepatitis C
Sie sind hier: